Fuller H B Co SEC Filings

H.B. Fuller (FUL) Executive VP and CFO reported insider activity on a Form 4. On 11/07/2025, the officer acquired 162.88 phantom units tied to common stock at a reference price of $57.87. Following this, the officer beneficially owns 27,363.18 phantom units.

The filing also shows 54,646 shares of common stock held directly after the reported activity. In addition, the officer holds multiple employee stock options and restricted stock units with stated vesting and expiration terms, reflecting ongoing equity-based compensation.

H.B. Fuller (FUL) reported insider activity by its Sr. VP, International Growth. On 11/07/2025, the officer acquired 37.47 phantom units (Transaction Code A), which convert into common stock on a 1-for-1 basis under the company plan.

Following the reported transactions, the officer beneficially owned 22,316.23 shares of common stock directly and 5,114.79 derivative units. The filing also lists outstanding employee stock options, including 21,834 options at $53.57 expiring 01/25/2028 and 19,520 options at $51.89 expiring 01/27/2031, alongside restricted stock units that vest in three annual installments beginning on their stated dates.

H.B. Fuller (FUL) Executive VP and CFO reported insider transactions. On 10/27/2025, the officer exercised 16,672 employee stock options at a $43.48 exercise price (code M) and sold 14,222 shares at a $60.3125 weighted average price (code S). After these trades, direct beneficial ownership stood at 54,646 common shares.

Separately, on 10/24/2025, the officer acquired 153.29 phantom units (code A), which convert into common stock on a 1‑for‑1 basis under the Key Employee Deferred Compensation Plan. The filing lists additional vested and time‑based option and RSU awards with stated expiration and vesting schedules.

Sale prices ranged from $60.02 to $60.9350, and the reporting person will provide full pricing details upon request.

H.B. Fuller (FUL) received a Form 144 notice for a proposed sale of 14,222 shares of common stock with an aggregate market value of $857,765.00. The filing lists an approximate sale date of 10/27/2025 on the NYSE through Charles Schwab & Co., Inc.

The shares were acquired on 10/27/2025 via an employee stock option exercise using a broker payment for cashless exercise. Shares outstanding were 54,088,889 at the time cited.

H.B. Fuller (FUL) senior vice president, International Growth, filed a Form 4 reporting an equity award update. On 10/24/2025, the reporting person acquired 35.26 phantom units at $61.49 per unit. Per the plan, these units convert into common stock on a 1-for-1 basis and may settle upon specified termination events. Following the transaction, the person beneficially owned 5,056.78 phantom units directly.

The filing shows 22,316.23 shares of common stock beneficially owned directly. It also lists employee stock options for 19,520, 21,834, 11,636, 10,831, 10,730 and 9,928 shares with exercise prices between $51.89 and $77.72, with stated vesting schedules and expirations from 01/25/2028 to 01/27/2035. Restricted stock units of 623.89, 1,139.13 and 1,918.46 convert 1-for-1 into common stock and vest in three annual installments beginning on the dates shown.

BlackRock, Inc. filed an amended Schedule 13G reporting beneficial ownership of 7,776,207 shares of H.B. Fuller (FUL), representing 14.4% of the common stock. As of 09/30/2025, BlackRock had 7,645,396 shares with sole voting power and 7,776,207 shares with sole dispositive power, with no shared voting or dispositive power disclosed.

BlackRock states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing notes that iShares Core S&P Small-Cap ETF has an interest in H.B. Fuller’s common stock that exceeds five percent.

H.B. Fuller (FUL) reported insider equity activity for its Executive VP and CFO on a Form 4. On 10/10/2025, the officer acquired 165.1 phantom units (1-for-1 into common stock), bringing total phantom units beneficially owned to 26,936.83, including amounts from a dividend equivalent feature. Following the reported transactions, the officer directly owned 52,196 shares of common stock.

The filing also lists multiple employee stock options with exercise prices between $43.48 and $77.72 and various expiration dates, plus restricted stock units that vest in three annual installments beginning on their stated grant dates.

H.B. Fuller (FUL) senior officer (Sr. VP, International Growth) reported insider activity on 10/10/2025. The filing shows an acquisition of 37.98 phantom units, which convert into common stock on a 1‑for‑1 basis.

Following the reported transactions, the officer beneficially owned 22,316.23 shares of common stock (direct). Derivative holdings included 5,021.52 phantom units after the update, plus various employee stock options and restricted stock units with stated exercise prices, vesting schedules, and expirations as disclosed.

H.B. Fuller Company announced the election of Celine Martin, age 51, as a Class III director effective December 1, 2025, with an initial term ending at the 2026 annual meeting. She will join the Audit and Compensation Committees. Ms. Martin most recently led the Cardiovascular & Specialty Solutions group at Johnson & Johnson from 2022–2025 and previously oversaw Ethicon’s surgical instrument portfolio. Her career spans roughly 30 years in medical device businesses across multiple geographies.

For board service she will receive an annual cash retainer of $100,000, an initial grant of 1,300 restricted stock units, and eligibility for an annual discretionary deferred phantom stock grant valued at $165,000. The board noted no direct or indirect material interest from Ms. Martin in customer-supplier transactions with Johnson & Johnson. The board size will increase to nine directors, eight of whom will be independent, effective December 1, 2025.